These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

971 related articles for article (PubMed ID: 16958996)

  • 41. A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
    Zavagno G; De Salvo GL; Scalco G; Bozza F; Barutta L; Del Bianco P; Renier M; Racano C; Carraro P; Nitti D;
    Ann Surg; 2008 Feb; 247(2):207-13. PubMed ID: 18216523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Eighteen sensations after breast cancer surgery: a two-year comparison of sentinel lymph node biopsy and axillary lymph node dissection.
    Baron RH; Fey JV; Borgen PI; Van Zee KJ
    Oncol Nurs Forum; 2004 Jul; 31(4):691-8. PubMed ID: 15252425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A nonrandomized follow-up comparison between standard axillary node dissection and sentinel node biopsy in breast cancer.
    Konstantiniuk P; Schrenk P; Reitsamer R; Koeberle-Wuehrer R; Tausch C; Roka S; Riedl O; Poestlberger S; Hecke D; Janauer M; Haid A
    Breast; 2007 Oct; 16(5):520-6. PubMed ID: 17566737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer.
    Crane-Okada R; Wascher RA; Elashoff D; Giuliano AE
    Ann Surg Oncol; 2008 Jul; 15(7):1996-2005. PubMed ID: 18415650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eighteen sensations after breast cancer surgery: a 5-year comparison of sentinel lymph node biopsy and axillary lymph node dissection.
    Baron RH; Fey JV; Borgen PI; Stempel MM; Hardick KR; Van Zee KJ
    Ann Surg Oncol; 2007 May; 14(5):1653-61. PubMed ID: 17295084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
    Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
    Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
    Noguchi M
    Eur J Surg Oncol; 2008 Feb; 34(2):129-34. PubMed ID: 17498911
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term follow-up results of breast cancer patients with sentinel lymph node biopsy using periareolar injection.
    Imasato M; Shimazu K; Tamaki Y; Taguchi T; Tanji Y; Kim SJ; Noguchi S
    Am J Surg; 2010 Apr; 199(4):442-6. PubMed ID: 19596117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.
    Neri A; Marrelli D; Roviello F; De Stefano A; Guarnieri A; Pallucca E; Pinto E
    Ann Surg Oncol; 2005 Mar; 12(3):246-53. PubMed ID: 15827817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy.
    Cox C; White L; Allred N; Meyers M; Dickson D; Dupont E; Cantor A; Ly Q; Dessureault S; King J; Nicosia S; Vrcel V; Diaz N
    Ann Surg Oncol; 2006 May; 13(5):708-11. PubMed ID: 16538416
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Very slight chance of other metastases in axillary nodes of breast cancer patients with a small sentinel node metastasis without extranodal tumor growth].
    van der Loo EM; Hop WC; Tervoort MA; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(19):938-43. PubMed ID: 15160561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study.
    Bulte CS; van der Heiden-van der Loo M; Hennipman A
    Eur J Surg Oncol; 2009 Jan; 35(1):25-31. PubMed ID: 18640809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stage migration with sentinel node biopsy in breast cancer.
    Layeequr Rahman R; Siegel E; Boneti C; Ingram M; Kepple J; Henry-Tillman RS; Klimberg VS
    Am J Surg; 2009 Apr; 197(4):491-6. PubMed ID: 19178897
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The accuracy of sentinel lymph node biopsy in multicentric and multifocal invasive breast cancers.
    Tousimis E; Van Zee KJ; Fey JV; Hoque LW; Tan LK; Cody HS; Borgen PI; Montgomery LL
    J Am Coll Surg; 2003 Oct; 197(4):529-35. PubMed ID: 14522317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.